LivaNova (NASDAQ:LIVN) Upgraded to "Strong-Buy" at StockNews.com

StockNews.com upgraded shares of LivaNova (NASDAQ:LIVN - Free Report) from a buy rating to a strong-buy rating in a research note published on Friday.

Several other research analysts have also issued reports on LIVN. Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 target price on shares of LivaNova in a research report on Tuesday, January 28th. Robert W. Baird increased their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Finally, Mizuho dropped their price target on LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, October 31st. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $69.17.

LivaNova Trading Down 1.0 %

NASDAQ LIVN traded down $0.47 on Friday, hitting $47.21. The company's stock had a trading volume of 468,064 shares, compared to its average volume of 445,979. The company's 50-day moving average is $48.25 and its 200 day moving average is $49.55. The firm has a market cap of $2.56 billion, a PE ratio of 112.40 and a beta of 1.00. LivaNova has a 1-year low of $43.15 and a 1-year high of $64.47. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Insider Activity

In related news, Director Francesco Bianchi sold 1,250 shares of the business's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

A number of institutional investors and hedge funds have recently made changes to their positions in LIVN. Russell Investments Group Ltd. raised its holdings in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after purchasing an additional 219 shares during the last quarter. Sterling Capital Management LLC lifted its position in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after acquiring an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division boosted its stake in LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock worth $191,000 after purchasing an additional 720 shares during the period. Captrust Financial Advisors bought a new position in shares of LivaNova during the third quarter worth $217,000. Finally, Sanctuary Advisors LLC purchased a new position in LivaNova during the 3rd quarter valued at approximately $219,000. Institutional investors own 97.64% of the company's stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.